Serveur d'exploration sur le lymphœdème

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Defining a threshold for intervention in breast cancer-related lymphedema: what level of arm volume increase predicts progression?

Identifieur interne : 001987 ( PubMed/Curation ); précédent : 001986; suivant : 001988

Defining a threshold for intervention in breast cancer-related lymphedema: what level of arm volume increase predicts progression?

Auteurs : Michelle C. Specht [États-Unis] ; Cynthia L. Miller ; Tara A. Russell ; Nora Horick ; Melissa N. Skolny ; Jean A. O'Toole ; Lauren S. Jammallo ; Andrzej Niemierko ; Betro T. Sadek ; Mina N. Shenouda ; Dianne M. Finkelstein ; Barbara L. Smith ; Alphonse G. Taghian

Source :

RBID : pubmed:23912961

Descripteurs français

English descriptors

Abstract

The purpose of this study is to evaluate arm volume measurements and clinico-pathologic characteristics of breast cancer patients to define a threshold for intervention in breast cancer-related lymphedema. We prospectively performed arm volume measurements on breast cancer patients using a Perometer. Arm measurements were performed pre- and post-operatively, and change in arm volume was quantified using a relative volume change (RVC) equation. Patient and treatment risk factors were evaluated. Cox proportional hazards models with time-dependent covariates for RVC were used to evaluate whether RVC elevations of ≥3 to <5 % or ≥5 to <10 % occurring ≤3 months or >3 months after surgery were associated with progression to ≥10 % RVC. 1,173 patients met eligibility criteria with a median of 27 months post-operative follow-up. The cumulative incidence of ≥10 % RVC at 24 months was 5.26 % (95 % CI 4.01-6.88 %). By multivariable analysis, a measurement of ≥5 to <10 % RVC occurring >3 months after surgery was significantly associated with an increased risk of progression to ≥10 % RVC (HR 2.97, p < 0.0001), but a measurement of ≥3 to <5 % RVC during the same time period was not statistically significantly associated (HR 1.55, p = 0.10). Other significant risk factors included a measurement ≤3 months after surgery with RVC of ≥3 to <5 % (p = 0.007), ≥5 to <10 % (p < 0.0001), or ≥10 % (p = 0.023), axillary lymph node dissection (ALND) (p < 0.0001), and higher BMI at diagnosis (p = 0.0028). Type of breast surgery, age, number of positive or number of lymph nodes removed, nodal radiation, chemotherapy, and hormonal therapy were not significant (p > 0.05). Breast cancer patients who experience a relative arm volume increase of ≥3 to <5 % occurring >3 months after surgery do not have a statistically significant increase in risk of progression to ≥10 %, a common lymphedema criterion. Our data support utilization of a ≥5 to <10 % threshold for close monitoring or intervention, warranting further assessment. Additional risk factors for progression to ≥10 % include ALND, higher BMI, and post-operative arm volume elevation.

DOI: 10.1007/s10549-013-2655-2
PubMed: 23912961

Links toward previous steps (curation, corpus...)


Links to Exploration step

pubmed:23912961

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Defining a threshold for intervention in breast cancer-related lymphedema: what level of arm volume increase predicts progression?</title>
<author>
<name sortKey="Specht, Michelle C" sort="Specht, Michelle C" uniqKey="Specht M" first="Michelle C" last="Specht">Michelle C. Specht</name>
<affiliation wicri:level="1">
<nlm:affiliation>Division of Surgical Oncology, Massachusetts General Hospital, 100 Blossom Street, Boston, MA 02114, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Surgical Oncology, Massachusetts General Hospital, 100 Blossom Street, Boston, MA 02114</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Miller, Cynthia L" sort="Miller, Cynthia L" uniqKey="Miller C" first="Cynthia L" last="Miller">Cynthia L. Miller</name>
</author>
<author>
<name sortKey="Russell, Tara A" sort="Russell, Tara A" uniqKey="Russell T" first="Tara A" last="Russell">Tara A. Russell</name>
</author>
<author>
<name sortKey="Horick, Nora" sort="Horick, Nora" uniqKey="Horick N" first="Nora" last="Horick">Nora Horick</name>
</author>
<author>
<name sortKey="Skolny, Melissa N" sort="Skolny, Melissa N" uniqKey="Skolny M" first="Melissa N" last="Skolny">Melissa N. Skolny</name>
</author>
<author>
<name sortKey="O Toole, Jean A" sort="O Toole, Jean A" uniqKey="O Toole J" first="Jean A" last="O'Toole">Jean A. O'Toole</name>
</author>
<author>
<name sortKey="Jammallo, Lauren S" sort="Jammallo, Lauren S" uniqKey="Jammallo L" first="Lauren S" last="Jammallo">Lauren S. Jammallo</name>
</author>
<author>
<name sortKey="Niemierko, Andrzej" sort="Niemierko, Andrzej" uniqKey="Niemierko A" first="Andrzej" last="Niemierko">Andrzej Niemierko</name>
</author>
<author>
<name sortKey="Sadek, Betro T" sort="Sadek, Betro T" uniqKey="Sadek B" first="Betro T" last="Sadek">Betro T. Sadek</name>
</author>
<author>
<name sortKey="Shenouda, Mina N" sort="Shenouda, Mina N" uniqKey="Shenouda M" first="Mina N" last="Shenouda">Mina N. Shenouda</name>
</author>
<author>
<name sortKey="Finkelstein, Dianne M" sort="Finkelstein, Dianne M" uniqKey="Finkelstein D" first="Dianne M" last="Finkelstein">Dianne M. Finkelstein</name>
</author>
<author>
<name sortKey="Smith, Barbara L" sort="Smith, Barbara L" uniqKey="Smith B" first="Barbara L" last="Smith">Barbara L. Smith</name>
</author>
<author>
<name sortKey="Taghian, Alphonse G" sort="Taghian, Alphonse G" uniqKey="Taghian A" first="Alphonse G" last="Taghian">Alphonse G. Taghian</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2013">2013</date>
<idno type="RBID">pubmed:23912961</idno>
<idno type="pmid">23912961</idno>
<idno type="doi">10.1007/s10549-013-2655-2</idno>
<idno type="wicri:Area/PubMed/Corpus">001987</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001987</idno>
<idno type="wicri:Area/PubMed/Curation">001987</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001987</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Defining a threshold for intervention in breast cancer-related lymphedema: what level of arm volume increase predicts progression?</title>
<author>
<name sortKey="Specht, Michelle C" sort="Specht, Michelle C" uniqKey="Specht M" first="Michelle C" last="Specht">Michelle C. Specht</name>
<affiliation wicri:level="1">
<nlm:affiliation>Division of Surgical Oncology, Massachusetts General Hospital, 100 Blossom Street, Boston, MA 02114, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Division of Surgical Oncology, Massachusetts General Hospital, 100 Blossom Street, Boston, MA 02114</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Miller, Cynthia L" sort="Miller, Cynthia L" uniqKey="Miller C" first="Cynthia L" last="Miller">Cynthia L. Miller</name>
</author>
<author>
<name sortKey="Russell, Tara A" sort="Russell, Tara A" uniqKey="Russell T" first="Tara A" last="Russell">Tara A. Russell</name>
</author>
<author>
<name sortKey="Horick, Nora" sort="Horick, Nora" uniqKey="Horick N" first="Nora" last="Horick">Nora Horick</name>
</author>
<author>
<name sortKey="Skolny, Melissa N" sort="Skolny, Melissa N" uniqKey="Skolny M" first="Melissa N" last="Skolny">Melissa N. Skolny</name>
</author>
<author>
<name sortKey="O Toole, Jean A" sort="O Toole, Jean A" uniqKey="O Toole J" first="Jean A" last="O'Toole">Jean A. O'Toole</name>
</author>
<author>
<name sortKey="Jammallo, Lauren S" sort="Jammallo, Lauren S" uniqKey="Jammallo L" first="Lauren S" last="Jammallo">Lauren S. Jammallo</name>
</author>
<author>
<name sortKey="Niemierko, Andrzej" sort="Niemierko, Andrzej" uniqKey="Niemierko A" first="Andrzej" last="Niemierko">Andrzej Niemierko</name>
</author>
<author>
<name sortKey="Sadek, Betro T" sort="Sadek, Betro T" uniqKey="Sadek B" first="Betro T" last="Sadek">Betro T. Sadek</name>
</author>
<author>
<name sortKey="Shenouda, Mina N" sort="Shenouda, Mina N" uniqKey="Shenouda M" first="Mina N" last="Shenouda">Mina N. Shenouda</name>
</author>
<author>
<name sortKey="Finkelstein, Dianne M" sort="Finkelstein, Dianne M" uniqKey="Finkelstein D" first="Dianne M" last="Finkelstein">Dianne M. Finkelstein</name>
</author>
<author>
<name sortKey="Smith, Barbara L" sort="Smith, Barbara L" uniqKey="Smith B" first="Barbara L" last="Smith">Barbara L. Smith</name>
</author>
<author>
<name sortKey="Taghian, Alphonse G" sort="Taghian, Alphonse G" uniqKey="Taghian A" first="Alphonse G" last="Taghian">Alphonse G. Taghian</name>
</author>
</analytic>
<series>
<title level="j">Breast cancer research and treatment</title>
<idno type="eISSN">1573-7217</idno>
<imprint>
<date when="2013" type="published">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Arm (physiopathology)</term>
<term>Breast Neoplasms (complications)</term>
<term>Breast Neoplasms (pathology)</term>
<term>Breast Neoplasms (surgery)</term>
<term>Breast Neoplasms (therapy)</term>
<term>Disease Progression</term>
<term>Female</term>
<term>Humans</term>
<term>Lymph Node Excision (adverse effects)</term>
<term>Lymphedema (epidemiology)</term>
<term>Lymphedema (etiology)</term>
<term>Lymphedema (pathology)</term>
<term>Mastectomy (adverse effects)</term>
<term>Middle Aged</term>
<term>Multivariate Analysis</term>
<term>Postoperative Period</term>
<term>Proportional Hazards Models</term>
<term>Prospective Studies</term>
<term>Time Factors</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Analyse multivariée</term>
<term>Bras (physiopathologie)</term>
<term>Facteurs temps</term>
<term>Femelle</term>
<term>Humains</term>
<term>Jeune adulte</term>
<term>Lymphadénectomie (effets indésirables)</term>
<term>Lymphoedème (anatomopathologie)</term>
<term>Lymphoedème (épidémiologie)</term>
<term>Lymphoedème (étiologie)</term>
<term>Mastectomie (effets indésirables)</term>
<term>Modèles de hasards proportionnels</term>
<term>Période postopératoire</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Tumeurs du sein ()</term>
<term>Tumeurs du sein (anatomopathologie)</term>
<term>Études prospectives</term>
<term>Évolution de la maladie</term>
</keywords>
<keywords scheme="MESH" qualifier="adverse effects" xml:lang="en">
<term>Lymph Node Excision</term>
<term>Mastectomy</term>
</keywords>
<keywords scheme="MESH" qualifier="anatomopathologie" xml:lang="fr">
<term>Lymphoedème</term>
<term>Tumeurs du sein</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en">
<term>Breast Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr">
<term>Lymphadénectomie</term>
<term>Mastectomie</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en">
<term>Lymphedema</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en">
<term>Lymphedema</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en">
<term>Breast Neoplasms</term>
<term>Lymphedema</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathologie" xml:lang="fr">
<term>Bras</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en">
<term>Arm</term>
</keywords>
<keywords scheme="MESH" qualifier="surgery" xml:lang="en">
<term>Breast Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en">
<term>Breast Neoplasms</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr">
<term>Lymphoedème</term>
</keywords>
<keywords scheme="MESH" qualifier="étiologie" xml:lang="fr">
<term>Lymphoedème</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Disease Progression</term>
<term>Female</term>
<term>Humans</term>
<term>Middle Aged</term>
<term>Multivariate Analysis</term>
<term>Postoperative Period</term>
<term>Proportional Hazards Models</term>
<term>Prospective Studies</term>
<term>Time Factors</term>
<term>Young Adult</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Analyse multivariée</term>
<term>Facteurs temps</term>
<term>Femelle</term>
<term>Humains</term>
<term>Jeune adulte</term>
<term>Modèles de hasards proportionnels</term>
<term>Période postopératoire</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Tumeurs du sein</term>
<term>Études prospectives</term>
<term>Évolution de la maladie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">The purpose of this study is to evaluate arm volume measurements and clinico-pathologic characteristics of breast cancer patients to define a threshold for intervention in breast cancer-related lymphedema. We prospectively performed arm volume measurements on breast cancer patients using a Perometer. Arm measurements were performed pre- and post-operatively, and change in arm volume was quantified using a relative volume change (RVC) equation. Patient and treatment risk factors were evaluated. Cox proportional hazards models with time-dependent covariates for RVC were used to evaluate whether RVC elevations of ≥3 to <5 % or ≥5 to <10 % occurring ≤3 months or >3 months after surgery were associated with progression to ≥10 % RVC. 1,173 patients met eligibility criteria with a median of 27 months post-operative follow-up. The cumulative incidence of ≥10 % RVC at 24 months was 5.26 % (95 % CI 4.01-6.88 %). By multivariable analysis, a measurement of ≥5 to <10 % RVC occurring >3 months after surgery was significantly associated with an increased risk of progression to ≥10 % RVC (HR 2.97, p < 0.0001), but a measurement of ≥3 to <5 % RVC during the same time period was not statistically significantly associated (HR 1.55, p = 0.10). Other significant risk factors included a measurement ≤3 months after surgery with RVC of ≥3 to <5 % (p = 0.007), ≥5 to <10 % (p < 0.0001), or ≥10 % (p = 0.023), axillary lymph node dissection (ALND) (p < 0.0001), and higher BMI at diagnosis (p = 0.0028). Type of breast surgery, age, number of positive or number of lymph nodes removed, nodal radiation, chemotherapy, and hormonal therapy were not significant (p > 0.05). Breast cancer patients who experience a relative arm volume increase of ≥3 to <5 % occurring >3 months after surgery do not have a statistically significant increase in risk of progression to ≥10 %, a common lymphedema criterion. Our data support utilization of a ≥5 to <10 % threshold for close monitoring or intervention, warranting further assessment. Additional risk factors for progression to ≥10 % include ALND, higher BMI, and post-operative arm volume elevation.</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">23912961</PMID>
<DateCreated>
<Year>2013</Year>
<Month>08</Month>
<Day>14</Day>
</DateCreated>
<DateCompleted>
<Year>2014</Year>
<Month>04</Month>
<Day>18</Day>
</DateCompleted>
<DateRevised>
<Year>2017</Year>
<Month>02</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1573-7217</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>140</Volume>
<Issue>3</Issue>
<PubDate>
<Year>2013</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>Breast cancer research and treatment</Title>
<ISOAbbreviation>Breast Cancer Res. Treat.</ISOAbbreviation>
</Journal>
<ArticleTitle>Defining a threshold for intervention in breast cancer-related lymphedema: what level of arm volume increase predicts progression?</ArticleTitle>
<Pagination>
<MedlinePgn>485-94</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s10549-013-2655-2</ELocationID>
<Abstract>
<AbstractText>The purpose of this study is to evaluate arm volume measurements and clinico-pathologic characteristics of breast cancer patients to define a threshold for intervention in breast cancer-related lymphedema. We prospectively performed arm volume measurements on breast cancer patients using a Perometer. Arm measurements were performed pre- and post-operatively, and change in arm volume was quantified using a relative volume change (RVC) equation. Patient and treatment risk factors were evaluated. Cox proportional hazards models with time-dependent covariates for RVC were used to evaluate whether RVC elevations of ≥3 to <5 % or ≥5 to <10 % occurring ≤3 months or >3 months after surgery were associated with progression to ≥10 % RVC. 1,173 patients met eligibility criteria with a median of 27 months post-operative follow-up. The cumulative incidence of ≥10 % RVC at 24 months was 5.26 % (95 % CI 4.01-6.88 %). By multivariable analysis, a measurement of ≥5 to <10 % RVC occurring >3 months after surgery was significantly associated with an increased risk of progression to ≥10 % RVC (HR 2.97, p < 0.0001), but a measurement of ≥3 to <5 % RVC during the same time period was not statistically significantly associated (HR 1.55, p = 0.10). Other significant risk factors included a measurement ≤3 months after surgery with RVC of ≥3 to <5 % (p = 0.007), ≥5 to <10 % (p < 0.0001), or ≥10 % (p = 0.023), axillary lymph node dissection (ALND) (p < 0.0001), and higher BMI at diagnosis (p = 0.0028). Type of breast surgery, age, number of positive or number of lymph nodes removed, nodal radiation, chemotherapy, and hormonal therapy were not significant (p > 0.05). Breast cancer patients who experience a relative arm volume increase of ≥3 to <5 % occurring >3 months after surgery do not have a statistically significant increase in risk of progression to ≥10 %, a common lymphedema criterion. Our data support utilization of a ≥5 to <10 % threshold for close monitoring or intervention, warranting further assessment. Additional risk factors for progression to ≥10 % include ALND, higher BMI, and post-operative arm volume elevation.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Specht</LastName>
<ForeName>Michelle C</ForeName>
<Initials>MC</Initials>
<AffiliationInfo>
<Affiliation>Division of Surgical Oncology, Massachusetts General Hospital, 100 Blossom Street, Boston, MA 02114, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Miller</LastName>
<ForeName>Cynthia L</ForeName>
<Initials>CL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Russell</LastName>
<ForeName>Tara A</ForeName>
<Initials>TA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Horick</LastName>
<ForeName>Nora</ForeName>
<Initials>N</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Skolny</LastName>
<ForeName>Melissa N</ForeName>
<Initials>MN</Initials>
</Author>
<Author ValidYN="Y">
<LastName>O'Toole</LastName>
<ForeName>Jean A</ForeName>
<Initials>JA</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Jammallo</LastName>
<ForeName>Lauren S</ForeName>
<Initials>LS</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Niemierko</LastName>
<ForeName>Andrzej</ForeName>
<Initials>A</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Sadek</LastName>
<ForeName>Betro T</ForeName>
<Initials>BT</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Shenouda</LastName>
<ForeName>Mina N</ForeName>
<Initials>MN</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Finkelstein</LastName>
<ForeName>Dianne M</ForeName>
<Initials>DM</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Smith</LastName>
<ForeName>Barbara L</ForeName>
<Initials>BL</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Taghian</LastName>
<ForeName>Alphonse G</ForeName>
<Initials>AG</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y">
<Grant>
<GrantID>P50 CA089393</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01 CA139118</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>P50CA089393</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
<Grant>
<GrantID>R01CA139118</GrantID>
<Acronym>CA</Acronym>
<Agency>NCI NIH HHS</Agency>
<Country>United States</Country>
</Grant>
</GrantList>
<PublicationTypeList>
<PublicationType UI="D016430">Clinical Trial</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2013</Year>
<Month>08</Month>
<Day>04</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>Netherlands</Country>
<MedlineTA>Breast Cancer Res Treat</MedlineTA>
<NlmUniqueID>8111104</NlmUniqueID>
<ISSNLinking>0167-6806</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList>
<CommentsCorrections RefType="Cites">
<RefSource>Lymphology. 2009 Dec;42(4):161-75</RefSource>
<PMID Version="1">20218084</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer. 1998 Dec 15;83(12 Suppl American):2776-81</RefSource>
<PMID Version="1">9874397</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Clin Oncol. 2008 Nov 10;26(32):5213-9</RefSource>
<PMID Version="1">18838709</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Natl Cancer Inst. 2001 Jan 17;93(2):96-111</RefSource>
<PMID Version="1">11208879</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Ann R Coll Surg Engl. 2003 May;85(3):158-61</RefSource>
<PMID Version="1">12831486</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Lymphat Res Biol. 2005;3(4):208-17</RefSource>
<PMID Version="1">16379589</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Work. 2009;34(3):285-96</RefSource>
<PMID Version="1">20037243</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer. 2001 Oct 1;92(7):1783-7</RefSource>
<PMID Version="1">11745250</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Surg. 2004 Jan;187(1):69-72</RefSource>
<PMID Version="1">14706589</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer. 2008 Jun 15;112(12):2809-19</RefSource>
<PMID Version="1">18428212</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Clin Oncol. 2007 Aug 20;25(24):3657-63</RefSource>
<PMID Version="1">17485711</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>CA Cancer J Clin. 2000 Sep-Oct;50(5):292-307; quiz 308-11</RefSource>
<PMID Version="1">11075239</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Clin Oncol. 2008 Jul 20;26(21):3536-42</RefSource>
<PMID Version="1">18640935</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Ann Surg Oncol. 2006 Apr;13(4):491-500</RefSource>
<PMID Version="1">16514477</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Acta Oncol. 2008;47(5):835-42</RefSource>
<PMID Version="1">18568481</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Am J Clin Oncol. 2011 Oct;34(5):506-10</RefSource>
<PMID Version="1">21127413</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Lancet Oncol. 2013 May;14(6):500-15</RefSource>
<PMID Version="1">23540561</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Int J Radiat Oncol Biol Phys. 2008 Dec 1;72(5):1449-55</RefSource>
<PMID Version="1">19028274</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Invest. 2005;23(1):76-83</RefSource>
<PMID Version="1">15779870</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Eur J Vasc Endovasc Surg. 1996 Nov;12(4):412-7</RefSource>
<PMID Version="1">8980428</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Phys Ther. 2012 Jan;92(1):152-63</RefSource>
<PMID Version="1">21921254</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Int J Radiat Oncol Biol Phys. 2011 Apr 1;79(5):1436-43</RefSource>
<PMID Version="1">20605339</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Surg Oncol. 2006 Nov;15(3):153-65</RefSource>
<PMID Version="1">17187979</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer. 1998 Dec 15;83(12 Suppl American):2814-6</RefSource>
<PMID Version="1">9874403</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Breast Cancer Res Treat. 2011 Nov;130(2):579-86</RefSource>
<PMID Version="1">21656272</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Lymphology. 2001 Mar;34(1):2-11</RefSource>
<PMID Version="1">11307661</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Acta Radiol. 2007 Jun;48(5):488-95</RefSource>
<PMID Version="1">17520423</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Natl Cancer Inst. 2006 May 3;98(9):599-609</RefSource>
<PMID Version="1">16670385</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Acta Oncol. 2000;39(3):393-7</RefSource>
<PMID Version="1">10987237</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1209-15</RefSource>
<PMID Version="1">12654429</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>N Z Med J. 2012 Mar 9;125(1351):29-39</RefSource>
<PMID Version="1">22426609</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Aust N Z J Surg. 2000 Jun;70(6):412-8</RefSource>
<PMID Version="1">10843395</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Epidemiol Biomarkers Prev. 2007 Apr;16(4):775-82</RefSource>
<PMID Version="1">17416770</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Breast Cancer Res Treat. 2011 Dec;130(3):981-91</RefSource>
<PMID Version="1">21761159</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Breast Cancer Res Treat. 2009 Jan;113(2):383-91</RefSource>
<PMID Version="1">18297429</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Br J Surg. 2007 Jul;94(7):833-4</RefSource>
<PMID Version="1">17335123</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Breast. 2012 Jun;21(3):314-20</RefSource>
<PMID Version="1">22342676</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Australas Radiol. 2006 Dec;50(6):578-82</RefSource>
<PMID Version="1">17107530</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Lymphology. 2010 Sep;43(3):118-27</RefSource>
<PMID Version="1">21226414</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Semin Radiat Oncol. 2003 Jul;13(3):214-25</RefSource>
<PMID Version="1">12903011</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Surg Res. 2001 Feb;95(2):147-51</RefSource>
<PMID Version="1">11162038</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Lymphology. 2009 Mar;42(1):1-9</RefSource>
<PMID Version="1">19499762</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Br J Surg. 2005 Mar;92(3):311-5</RefSource>
<PMID Version="1">15672436</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Indian J Cancer. 2004 Jan-Mar;41(1):8-12</RefSource>
<PMID Version="1">15105573</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Br J Cancer. 2004 Oct 4;91(7):1229-35</RefSource>
<PMID Version="1">15305188</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Breast Cancer Res Treat. 2005 Feb;89(3):221-6</RefSource>
<PMID Version="1">15754119</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>BMJ. 2010;340:b5396</RefSource>
<PMID Version="1">20068255</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer. 2001 Sep 15;92(6):1368-77</RefSource>
<PMID Version="1">11745212</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Lymphology. 2008 Mar;41(1):18-28</RefSource>
<PMID Version="1">18581955</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Plast Reconstr Surg. 2012 May;129(5):789e-95e</RefSource>
<PMID Version="1">22544109</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Oncol Nurs Forum. 2009 Mar;36(2):185-93</RefSource>
<PMID Version="1">19273407</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>QJM. 2005 May;98(5):343-8</RefSource>
<PMID Version="1">15820971</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Lymphology. 2006 Dec;39(4):193-200</RefSource>
<PMID Version="1">17319632</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Clin Oncol. 2009 Jan 20;27(3):390-7</RefSource>
<PMID Version="1">19064976</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Ann Surg Oncol. 2010 Dec;17(12):3278-86</RefSource>
<PMID Version="1">20574774</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Oncologist. 2013;18(4):350-2</RefSource>
<PMID Version="1">23576481</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Lymphoedema. 2008 Oct 1;3(2):38-44</RefSource>
<PMID Version="1">20657749</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Lymphology. 1997 Jun;30(2):77-97</RefSource>
<PMID Version="1">9215977</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Clin Oncol. 2008 Dec 10;26(35):5689-96</RefSource>
<PMID Version="1">19001331</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Clin Oncol. 2009 Apr 20;27(12):2007-14</RefSource>
<PMID Version="1">19289624</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Clin Nurs. 2008 Jun;17(11):1450-9</RefSource>
<PMID Version="1">18482142</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Cancer Epidemiol Biomarkers Prev. 2010 Nov;19(11):2734-46</RefSource>
<PMID Version="1">20978176</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>J Surg Oncol. 2010 Jan 1;101(1):84-91</RefSource>
<PMID Version="1">19924721</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Breast Cancer Res Treat. 2002 Sep;75(1):51-64</RefSource>
<PMID Version="1">12500934</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="Cites">
<RefSource>Ann Surg Oncol. 2009 Jul;16(7):1959-72</RefSource>
<PMID Version="1">19365624</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D001132" MajorTopicYN="N">Arm</DescriptorName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D001943" MajorTopicYN="N">Breast Neoplasms</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
<QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008197" MajorTopicYN="N">Lymph Node Excision</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008209" MajorTopicYN="N">Lymphedema</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
<QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>
<QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008408" MajorTopicYN="N">Mastectomy</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D011184" MajorTopicYN="N">Postoperative Period</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>
</MeshHeading>
</MeshHeadingList>
<OtherID Source="NLM">NIHMS512552</OtherID>
<OtherID Source="NLM">PMC3788652</OtherID>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="received">
<Year>2013</Year>
<Month>07</Month>
<Day>22</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted">
<Year>2013</Year>
<Month>07</Month>
<Day>26</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez">
<Year>2013</Year>
<Month>8</Month>
<Day>6</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2013</Year>
<Month>8</Month>
<Day>6</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2014</Year>
<Month>4</Month>
<Day>20</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">23912961</ArticleId>
<ArticleId IdType="doi">10.1007/s10549-013-2655-2</ArticleId>
<ArticleId IdType="pmc">PMC3788652</ArticleId>
<ArticleId IdType="mid">NIHMS512552</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001987 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001987 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    LymphedemaV1
   |flux=    PubMed
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:23912961
   |texte=   Defining a threshold for intervention in breast cancer-related lymphedema: what level of arm volume increase predicts progression?
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i   -Sk "pubmed:23912961" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a LymphedemaV1 

Wicri

This area was generated with Dilib version V0.6.31.
Data generation: Sat Nov 4 17:40:35 2017. Site generation: Tue Feb 13 16:42:16 2024